Development of a novel, low-cost, transdermal drug delivery patch with enhanced API stabilisation

Amaphase is developing a novel and versatile transdermal patch for use across multiple applications from pain relief to chronic skin conditions. Its patented technology allows Active Pharmaceutical Ingredients to be stabilised for long periods without the need for harmful preservatives and, once activated by the user, will facilitate deeper and more efficient delivery into the skin through an innovative sequence of materials science and chemistry-based events. The company has employed experienced industrial designers throughout the prototype development phase to work in parallel with the formulation of the chemistry to investigate and create solutions which enhance the whole user experience from first use to disposal. Maximising ease of use for self-care to achieve medicines adherence in an ageing population with chronic conditions poses a number of challenges, not least mobility, dexterity, strength, single handed application, removal and safe disposal. The aim is to take a fresh look at self-administered treatments where ease and simplicity of use will significantly contribute to the likelihood of market success.